Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
B-cells
|
| gptkbp:associated_with |
gptkb:HIV
autoimmune diseases helicobacter pylori infection |
| gptkbp:clinical_trial |
ongoing studies
combination therapies phase II trials phase III trials |
| gptkbp:end_of_life |
approximately 30-40% for advanced stages
approximately 60-70% for early stages |
| https://www.w3.org/2000/01/rdf-schema#label |
large B-cell lymphoma
|
| gptkbp:is_a |
gptkb:healthcare_organization
|
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:research_focus |
biomarkers
genetic mutations new therapies |
| gptkbp:risk_factor |
age
family history gender exposure to certain chemicals previous cancer treatment |
| gptkbp:social_responsibility |
CT scan
biopsy varies by stage PET scan |
| gptkbp:symptoms |
weight loss
fever night sweats |
| gptkbp:treatment |
gptkb:vaccine
gptkb:R-CHOP gptkb:drug radiation therapy chemotherapy stem cell transplant R-EPOCH |
| gptkbp:type_of |
gptkb:primary_mediastinal_B-cell_lymphoma
gptkb:B-cell_lymphoma,_unclassifiable diffuse large B-cell lymphoma |
| gptkbp:bfsParent |
gptkb:Yescarta
gptkb:Kymriah |
| gptkbp:bfsLayer |
4
|